


Yearly Report 2025

PharmacoEpidemiology and Drug Safety Research Group (PharmaSafe)
Section for Pharmaceutics and Social Pharmacy
Department of Pharmacy
Faculty of Mathematics and Natural Sciences
University of Oslo



I got my
VACCINE

Contribution from Hedvig Nordeng, Mahmoud Zidan, Akhila Reddy, Emilie Willoch Olstad, Alexis Carson, Marleen van Gelder, Anne Gerd Granås, Milica Zugic, Kristina Gervin, Saeed Hayati, Anteneh A. Desalegn and Lavin Kadir.

Key Numbers 2025:

21 MASTER STUDENTS

77 SCIENTIFIC PUBLICATIONS

64 POSTERS/ORAL PRESENTATIONS/EXTERNAL LECTURES

29 MEDIA COVERAGES

11 INTERNATIONAL GUEST RESEARCHERS

15 RESEARCH GRANTS AWARDED (TOTAL OF 29,8 MILL. NOK)

- Key Numbers **2024**: 2 PhD defenses, 71 scientific publications, 81 posters/oral presentations/external lectures, 90 media coverages, 7 visits from international guest lecturers, 25 research grants awarded (a total of 7,4 MILL NOK)
- Key Numbers **2023**: 4 PhD defenses, 59 scientific publications, 77 posters/oral presentations/external lectures, 185 media coverages, 9 visits from international guest lecturers, 18 research grants awarded (a total of 14,9 MILL NOK)
- Key numbers **2022**: 4 PhD defenses, 54 scientific publications, 74 posters/oral presentations/external lectures, 63 media coverages, 4 visits from international guest lecturers, 5 research grants awarded (11.3 MILL NOK).
- Key numbers **2021**: 2 PhD defenses, 51 scientific publications, 42 posters/oral presentations/external lectures, 25 media coverages, 9 multimedia events, 4 visits from international guest lecturers, 6 research grants awarded.
- Key numbers **2020**: 34 international publications, 13 posters, 6 oral presentations/external lectures, >50 media coverages, 4 visits from international guest lecturers, 7 research grants awarded (10 MILL NOK).
- Key numbers **2019**: 31 scientific publications, 10 clinical guidelines, 20 posters, 33 oral presentations/external lectures, 39 media coverages, 4 visits from international guest lecturers, 6 PhD defense committees as an international member.
- Key Numbers **2018**: 43 scientific publications, 25 posters, 40 oral presentations/external lectures, 23 media coverages, 7 visits from international guest lecturers
- Key Numbers **2017**: 50 scientific publications, 30 posters, 44 oral presentations/external lectures, 13 media coverages, 6 visits from international guest lecturers

Prizes

1. **Fellow of the International Society for Pharmacoepidemiology (FISPE)**

Recipient: **Marleen van Gelder**

Awarded by: International Society for Pharmacoepidemiology (ISPE)

Description: This prestigious fellowship recognizes sustained excellence and leadership in the field of pharmacoepidemiology.

2. **James G. Wilson Publication Award**

Recipients: **Nhung Trinh** and colleagues

Awarded by: Society for Birth Defects Research and Prevention (BDRP)

Description: Awarded for the best paper published in the journal *Birth Defects Research*, recognizing outstanding contributions to the field of teratology and birth defects research.

3. **Best Paper Finalist 2025**

Recipients: Nuria Mercadé-Besora N, **Nhung Trinh**, **Hedvig Nordeng**, and colleagues

Awarded by: Heart BMJ

Description: Finalist for the Best Paper Award 2025 for the paper "The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications." This award is given by the Heart editorial team for papers demonstrating a high level of clinical relevance and research design.

4. **Poster award**

Recipients: Michele Fusaroli, **Nhung Trinh**, and colleagues

Awarded by: International Society of Pharmacovigilance (ISoP)

Description: Poster award at the 24th Annual Meeting of the International Society of Pharmacovigilance (ISoP 2025) for the poster "The Oslo Workshop: A collaboration to explore and compare existing tools for retrieving pregnancy reports from VigiBase"

5. **1st prize Poster Slam NorPEN**

Recipient: **Alexis Carson**

Awarded by: Nordic Pharmacoepidemiological Network (NorPEN) Scientific Committee

Description: Awarded for the best_PharmaSLAM presentation at the NorPEN 2025.

Scientific publications

Medications in Pregnancy

1. Hemmingsen CH, Kjaer SK, Hjorth S, Nörby U, Broe A, Pottegård A, Bénévent J, Schmiegelow K, Skovlund CW, Leinonen MK, **Nordeng H**, Mørch LS, Hargreave M. Maternal use of hormonal contraception and risk of childhood leukemia: A Scandinavian population-based cohort study. *Eur J Cancer*. 2025 Jan 17;215:115168.
2. Johnson H, Hjorth S, Morris J, Pottegård A, Leinonen M, Norby U, **Nordeng H**. Use of signal detection methods to identify associations between prenatal medication exposure and subsequent childhood cancers: a Nordic hypothesis-generating registry-based study. *Expert Opin Drug Saf*. 2025 Feb 12:1-12.
3. Boissiere-O'Neill T, **van Gelder MMHJ**, Engjom HM, **Nordeng HME**. Exposure to systemic antimicrobials during pregnancy and risk of miscarriage: A population-based registry study. *BJOG*. 2025 Mar 28.
4. **Reddy AS**, Fawad F, Leite MA, **Olstad EW**, **Gervin K**, Kanduri C, Sandve GK, Brandlistuen R, **Lupattelli A**, von Koss Torkildsen J, **Nordeng HME**. Prenatal exposure to psychotropics and analgesics on cognitive, linguistic and educational outcomes - a scoping review with focus on validity and reliability of outcome measures. *BMC Pregnancy Childbirth*. 2025 Mar 3;25(1):234.
5. Camanni M, **van Gelder MMHJ**, Cantarutti A, **Nordeng H**, **Lupattelli A**. Association of Prenatal Exposure to Triptans, Alone or Combined With Other Migraine Medications, and Neurodevelopmental Outcomes in Offspring. *Neurology*. 2025 Jun 24;104(12):e213678.
6. Hemmingsen CH, Kjaer SK, Hjorth S, Nörby U, Pottegård A, Mathiasen R, Skovlund CW, Leinonen MK, **Nordeng H**, Mørch LS, Hargreave M. Maternal hormonal contraceptive use and childhood central nervous system tumor risk in a large Scandinavian cohort. *Int J Cancer*. 2025 Jun 5. doi: 10.1002/ijc.35509. Epub ahead of print. PMID: 40470656.
7. **Carson AC**, **Trinh NTH**, **Nordeng H**, Liu X, Munk-Olsen T, Eberhard-Gran M, Magnus P, **Lupattelli A**. Initiating antidepressant treatment in pregnancy: Timing, intensity, and influential maternal and familial factors. *J Affect Disord*. 2025 Jun 21;388:119726. doi: 10.1016/j.jad.2025.119726. Epub ahead of print. PMID: 40550280.
8. Bernhardsen GP, Pesonen M, Keski-Nisula L, **Nordeng H**, Lehto SM. Trajectories of Selective Serotonin Reuptake Inhibitor Use in Pregnancy and Perinatal Outcomes: A Longitudinal Register Study. *BJOG*. 2025 Aug 20. doi: 10.1111/1471-0528.18337. Epub ahead of print. PMID: 40836389,
9. Christensen JJ, Holven KB, Bogsrud MP, Retterstøl K, Roeters van Lennep JE, Michelsen TM, Veierød MB, **Nordeng H**. Statin use in pregnancy and risk of congenital malformations: a Norwegian nationwide study. *Eur Heart J*. 2025 Aug 21:ehaf592. doi: 10.1093/eurheartj/ehaf592. Epub ahead of print. PMID: 40838827.
10. Damkier P, Huybrechts KF, **Nordeng H**. Big Data in the Assessment of Medication Safety in Pregnancy: Opportunities and Challenges. *Paediatr Drugs*. 2025 Sep 4. doi: 10.1007/s40272-025-00718-1. Epub ahead of print. PMID: 40906238.

11. van Wijk EJC, **Zugic M**, Rostami S, **van Gelder MMHJ**, Ahmad AS, Sitras V, Spigset O, **Lupattelli A**, **Trinh NTH**. Gestational weight gain and postpartum weight retention: What is the role of perinatal antidepressant use? *J Affect Disord*. 2025 Oct 27;120521. doi: 10.1016/j.jad.2025.120521. Epub ahead of print. PMID: 41161536.
12. **Reddy AS**, **van Gelder MMHJ**, **Olstad EW**, **Gervin K**, von Koss Torkildsen J, **Nordeng H**. Prevalence of Neurodevelopmental Disorders in Families of Women Taking Psychotropic Medication During Pregnancy. *Paediatr Perinat Epidemiol*. 2025 Oct 30. doi: 10.1111/ppe.70075. Epub ahead of print. PMID: 41166062.
13. **Zugic M**, **Trinh NTH**, Rostami S, **Nordeng H**, **Ystrom E**, Bulik C M, Rø Ø, Andreassen O A, Magnus P, **Lupattelli A**. Antenatal depressive and anxiety symptoms in women with eating disorders who continue or discontinue antidepressant treatment in pregnancy. *Journal of Affective Disorders Reports*. 2025 Dec. doi: 10.1016/j.jadr.2025.100985.
14. Bernhardsen GP, Pesonen M, Keski-Nisula L, **Nordeng H**, Lehto SM. Trajectories of Selective Serotonin Reuptake Inhibitor Use in Pregnancy and Perinatal Outcomes: A Longitudinal Register Study. *BJOG*. 2026 Jan;133(1):83-94. doi: 10.1111/1471-0528.18337. Epub 2025 Aug 20. PMID: 40836389.
15. Carlsen SE, Hargreave M, Jarden E, Hemmingsen CH, Schmidt L, Hjorth S, Leinonen MK, Nørby M, Mørch LS, Kjær SK, Nordeng H. Maternal hormonal contraception use and the risk of childhood cancer: A systematic review and meta-analysis. *Accepted*.
16. Eun-Young, **van Gelder MMHJ**, Geisler BP, In-Sun O, **Nordeng HME**. Anti-Rheumatic Medication Use among Pregnant Women with Rheumatic Diseases – a Norwegian nationwide drug utilization study. *Accepted*.
17. Chatha ZF, **Trinh NTH**, Rostami S, Bergink V, **Carson A**, Magnus P, **Lupattelli A**. Timing of antidepressant initiation postpartum and maternal mental health outcomes up to 18 months after childbirth. *In revision*.
18. **Trinh NTH**, Rostami S, Pedroncelli M, Cheesman R, Magnus P, Johansson S, Andreassen OA, **Lupattelli A**. Prenatal antidepressant exposure and longitudinal differences in body mass index up to 8 years of age in the offspring born to mothers with pre-pregnancy depressive and/or anxiety in the Norwegian Mother, Father and Child Cohort Study. *In revision*.
19. Meng LC, **van Gelder MMHJ**, Chuang HM, Lai HY, Chen LK, Hsiao FY, **Nordeng HME**. Valproate Use by Fathers During Spermatogenesis and Risk of Neurodevelopmental Disorders in Children: A Cross-National Study from Norway and Taiwan. *In revision*.
20. Dolk H, Damase-Michel C, Morris J, Neville A, Garne E, Jordan S, Rissmann A, Coi A, Folan D, Broekstra D, Broughan JM, Bruneau L, Cavaero-Carbonell C, Den Hond E, Gatt M, Gissler M, Khoshnood B, Bielenska L, **Nordeng H**, Odak L, O'Mahony M, Perthuis I, Richardson JL, Rouget F, Sichitiu J, Tucker D, Zymak-Zakutnya N, Loane M. The EUROmediCAT network and databases: a resource for pharmacovigilance in pregnancy Short running title: The EUROmediCAT network and databases. Preprint: (Authorea, 2025) DOI: 10.22541/au.175394925.50330509/v1. *In revision*.

21. Nehard R, Faure Bardon V, Coulm B, Elefant E, Brochet MS, **van Gelder MMHJ**, Dechartres A, Marin B. Medication use during pregnancy in Europe and North America: a systematic review. *Submitted*.
22. Damkier P, **van Gelder MMHJ**, Huybrechts K, Meng LC, Hernandez-Diaz S, Nielsen J, Nørgård B, **Nordeng H**. Paternal use of metformin and risk of major congenital malformations: a meta-analysis of 4 studies. *Submitted*.
23. Björkström Gram E, Lund LC, Bjødstrup Jensen P, Hallas J, Bliddal M, Broe A, Chambers C, Munk-Olsen T, Wesselhoeft R, **Nordeng H**, Damkier P. Prescription use of acetaminophen during pregnancy and risk of ASD and ADHD in early childhood. *Submitted*.
24. Strassmann V, Gault N, Stark AK, Vaillant T, Berbain T, Martirosyan L, Macolic Sarinic V, **Nordeng HME**. Safety of Multiple Sclerosis Treatments During Pregnancy: An Overview of the EU Regulatory Approach to Pharmacovigilance and Data Collection. *Submitted*.
25. Christensen J, Trabjerg B, van Gelder MMHJ, Meng L-C, Lai H-Y, Igland J, Razaz N, Tomson T, Bjørk M-H, Hsiao F-Y, Nordeng HME, Dreier JW. The risk of neurodevelopmental disorders associated with paternal use of valproate during spermatogenesis: a living meta-analysis. *Submitted*.
26. Abtahi S, Duran-Salinas C, Gamba M, Comberg E, Han S, Llorente García A, Castillo Cano B, Garcia-Poza P, Martín-Pérez M, Souverein P, Caillet A, Beau A-B, Damase-Michel C, Martikainen V, Leinonen M, **Hayati S, Zidan M, Nordeng H**, Ouchi D, Giner-Soriano M, Santacà K, Ingrasciotta Y, Luxi N, Llopis F, Rodríguez C, Sanfelix G, Roberto G, Gini R, Mohammadi S, Riera-Arnau J, Hoxhaj V, Bonaterra-Pastra A, Riefolo F, Plueschke K, de Vries C, Restrepo-Méndez MC, Klungel O, Sturkenboom M. The utilisation of antiepileptic medications in pregnant women: a multi-database study from European countries. *In preparation*.

Breast Milk Studies

27. Macente J, Nauwelaerts N, Badée JM, Bonan RH, Huang MC, Van Neste M, Smits A, Allegaert K, **Nordeng H**, Hovd M, Martins FS, Annaert P. Predicting Drug Transfer Into Human Milk With the Simcyp Simulator: A Contribution From the ConcePTION Project. *CPT Pharmacometrics Syst Pharmacol*. 2025 Jul 9. doi: 10.1002/psp4.70066. Epub ahead of print. PMID: 40632507.
28. Liu X, Madsen KB, Zhu JL, Munk-Olsen T, Damkier P, **Lupattelli A**, Zoega H, **Nordeng H**, Kjeldsen MZ, Mægbæk ML, Madsen MG, Bergink V, Bliddal M. Psychotropic Medication Exposure via Breast Milk: A Population-Based Descriptive Study in Denmark. *Paediatr Perinat Epidemiol*. 2025 Sep 11. doi: 10.1111/ppe.70074. Epub ahead of print. PMID: 40931951.
29. Baklouti S, Rigourd V, Panchaud A, **Nordeng H**, Allegaert K, Annaert P, Huang M-C, Monfort A, Guidi M, Gandia P. Population pharmacokinetic modelling of amoxicillin in human breast milk – A contribution from the ConcePTION project. *Accepted*.

Methods

30. Abellan A, Burn E, **Trinh NTH**, Burkard T, Callahan A, Fernández-Bertolín S, Hurley E, Rodriguez C, Segundo E, Morales DR, **Nordeng HME**, Duarte-Salles T. Expanding the OMOP Common Data Model to Support Perinatal Research in Network Studies. *Pharmacoepidemiol Drug Saf.* 2025 Feb;34(2):e70106.
31. **Olstad EW**, **Nordeng H**, Bjørk MH, Selmer KK, **Gervin K**. Agreement Between Parental Self-Reported Antiseizure Medication Use and Dispensed Prescription Records From a National Prescription Database. *Pharmacoepidemiol Drug Saf.* 2025 Apr;34(4):e70139.
32. Sakai T, **Nordeng H**, **van Gelder MMHJ**. Longitudinal Methods Versus Multiple Imputation to Infer Missing Maternal Data in Registry-Based Pregnancy Studies. *Paediatr Perinat Epidemiol.* 2025 Jun 27. doi: 10.1111/ppe.70011. Epub ahead of print. PMID: 40576612.
33. Beau AB, Paoletti O, Bénévent J, Beslay M, Moisset X, Ballardini E, Barrachina-Bonet L, Cavero-Carbonell C, Coldea A, García-Villodre L, Geldhof A, Gini R, Gissler M, Jordan S, Leinonen MK, Manfrini M, Martikainen V, Mitter VR, Morris JK, Neville AJ, **Nordeng H**, Puccini A, Mo J, Damase-Michel C. Identifying Maternal Conditions Leading to Gabapentinoid Prescriptions in Pregnancy Using Electronic Health Records from Six European Countries: A Contribution from the IMI ConcePTION Project. *Drug Saf.* 2025 Jun 13. doi: 10.1007/s40264-025-01565-2. Epub ahead of print. PMID: 40514582.
34. Guntschnig S, Barbosa R, Jenzer H, Greening M, Hayde J, Heery H, Iglesias Serrano MC, Lajtmanová K, Rossin E, Tentova-Pecceva S, Kohl S, **Mulac A**. Tackling medication errors: how a systems approach improves patient safety. *Eur J Hosp Pharm.* 2025 Apr 30:ejhpharm-2025-004533. doi: 10.1136/ejhpharm-2025-004533. Epub ahead of print. PMID: 40280735.
35. Beslay M, Beau AB, Messina D, Benevent J, Ballardini E, Barrachina-Bonet L, Cavero-Carbonell C, Coldea A, García-Villodre L, Geldhof A, Gini R, Hellwig K, Jordan S, Leinonen MK, Lopez-Leon S, Manfrini M, Martikainen V, Mitter VR, Neville AJ, **Nordeng H**, Puccini A, Vukusic S, Damase-Michel C, Geissbühler Y, Morris JK. Methods of estimating prevalence of multiple sclerosis in six European healthcare data sources: a contribution from the ConcePTION project. *Eur J Epidemiol.* 2025 Jul 31. doi: 10.1007/s10654-025-01243-8. Epub ahead of print. PMID: 40742695.
36. Kanduri C, Mamica M, **Olstad EW**, Zucknick M, Li JJ, Sandve GK. Beware of counter-intuitive levels of false discoveries in datasets with strong intra-correlations. *Genome Biol.* 2025 Aug 18;26(1):249. doi: 10.1186/s13059-025-03734-z. PMID: 40826107; PMCID: PMC12359981.
37. Given J, Paoletti O, Bromley R, Ballardini E, Beau AB, Bartolini C, Caillet A, Coldea A, Damase-Michel C, Evans HT, Jordan S, Leinonen MK, Manfrini M, Martikainen V, Morris JK, Neville AJ, **Nordeng H**, Puccini A, Coste F, Loane M. The Effect of Different Algorithms on Prevalence of Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder in Secondary Healthcare Data in Five European Countries: A Contribution from the

- ConcePTION Project. J Autism Dev Disord. 2025 Aug 22. doi: 10.1007/s10803-025-06997-4. Epub ahead of print. PMID: 40844687.
38. Lopez-Leon S, Wen X, Gaitonde S, Afonso AS, Colas S, DiSantostefano RL, Kürzinger ML, Le Noan-Lainé M, **Mitter VR**, Murray G, Sabidó M, Scotto J, Jacobson MH, Bromley RL, Sarayani A. A Systematic Review of Algorithms for Identifying Pediatric Neurodevelopmental Outcomes. *Pharmacoepidemiol Drug Saf.* 2025 Sep;34(9):e70196. doi: 10.1002/pds.70196. PMID: 40967198; PMCID: PMC12445936.
 39. Mølgaard-Nielsen D, Mitter V, **Lupattelli A**, Hoxhaj V, Andaur Navarro CL, **Hayati S**, Lopez-Leon S, Morris JK, Geldof A, Jordan S, Leinonen MK, Martikainen V, Manfrini M, Cammarota L, Neville A, Barrachina-Bonet L, Cervero-Carbonell C, García-Villodre L, Caillet A, Beslay M, Damase-Michel C, **van Gelder MMHJ**, **Nordeng H**. Identification of gestational diabetes mellitus in European electronic healthcare databases: insights from the ConcePTION project. *BMJ Open.* 2025 Oct 5;15(10):e102343. doi: 10.1136/bmjopen-2025-102343. PMID: 41047268; PMCID: PMC12506240.
 40. **Zugic, M.**, Pejic, N., **Hayati, S.**, **van Gelder, MMHJ**, **Nordeng, H**. Development of a novel adherence scale for antidepressants in pregnancy: results from a cross-sectional study. *In revision*
 41. Lopez-Leon S, Mølgaard-Nielsen D, Mitter VR, **Lupattelli A**, Hoxhaj V, Andaur Navarro C, Hayati S, Morris, Leinonen MK, Martikainen V, Jordan S, Manfrini M, Barrachina-Bonet L, Cervero-Carbonell C, Caillet A, Damase-Michel C, **van Gelder MMHJ**, **Nordeng H**. Identifying Preeclampsia in European Electronic Healthcare Data: Insights from the ConcePTION Project. *Submitted.*
 42. Given J, Bromley R, Paoletti O, Afonso A, Ballardini E, Beau A-B, Bartolini C, Caillet A, Coldea A, Damase-Michel C, Evans HT, Grace E, Jordan S, Leinonen MK, Manfrini M, Martikainen V, Morris JK, Neville AJ, **Nordeng H**, Puccini A, Coste F, Loane M. Algorithms to estimate prevalence of intellectual disability in children in administrative data and recommendations for future studies: A contribution from the ConcePTION project using data from five European countries. *Submitted.*
 43. Beau AB, Paoletti O, Benevent J, Beslay M, Moisset X, Barrachina-Bonet L, Cervero-Carbonell C, Geldhof A, Gini R, Gissler M, Jordan S, Leinonen MK, Manfrini M, Martikainen V, Mitter VR, Morris JK, Neville AJ, **Nordeng H**, Mo J, Damase-Michel C. Using markers in administrative health care data sources to identify reason for gabapentinoids prescribing in pregnancy: results from six European countries - A contribution from the IMI ConcePTION project. *Drug Safety. Submitted.*
 44. Limoncella G, Girardi A, Bartolini C, Hyeraci G, Roberto G, Paoletti O, Messina D, Villalobos F, Bisacco CA, van den Berg J, Houben E, Santacà K, Ingrassiotta Y, Trifirò G, Pellegrini G, Ientile V, Hoxhaj V, Durán C, Riera-Arnau J, García-Poza P, Martín-Pérez M, Llorente-García A, Cea-Soriano L, Huerta-Álvarez C, Sánchez-Sáez F, Sanfélix-Gimeno G, Rodríguez-Bernal CL, Jové J, Bernard MA, Thurin NH, Jordan S, Thayer D, Evans HT, Coldea AI, Manfrini M, **van Gelder M**, Tari M, Pajouheshnia R, Afonso ASM, Le Noan-Lainé M, Mølgaard-Nielsen D, Cunningham M, Dodd C, Grilli L, Andaur Navarro CL, Sturkenboom M, **Nordeng H**, Gini

- R. Identifying pregnancies in population-based data sources: development and application of the ConcePTION Pregnancy Algorithm. *Submitted*.
45. Sakai T, **Nordeng H, van Gelder MMHJ**. Response to: Is the Most Likely Value Also the Best Imputation? *Paediatr Perinat Epidemiol*. *Submitted*.
 46. Wurst KE, Dolk H, Geldhof A, Neville A, Coste F, Jordan S, Loane M, Beau A, Bénévent J, Bromley R, Given J, Mølgaard-Nielsen D, **Nordeng H**, Sabidó M, Morris JK, Zeitlin J, Afonso A, Damase-Michel C. Core data elements for generating medicine safety evidence in pregnancy based on secondary use of real-world data: Recommendations from IMI-ConcePTION. *In preparation*.
 47. Lim H, Choi EY, Cho Y, Lai E, Chuang A, Man K, Chan A, Tran D, Harvard A, Yuen A, **Nordeng H, van Gelder M, Trinh NTH**, Cesta C, Reutfors J, Karlsson P, Bliddal M, Shin JY. Global Trends of Antidepressants Use During Pregnancy. *In preparation*.

Medication & Elderly

48. **Josendal AV**, Bergmo TS. Impact of electronic prescribing on medication changes in users of multidose drug dispensing. *Explor Res Clin Soc Pharm*. 2025 Oct 2;20:100667. doi: 10.1016/j.rcsop.2025.100667. PMID: 41142510; PMCID: PMC12547828.
49. **Josendal AV**, Sobakk OM, **Granås AG**, Eek AK. The use of direct oral anticoagulants (DOAC) in elderly patients – a study of interactions, anticholinergic and fall-risk increasing drugs. *In revision*.

Pharmacogenetics and -epigenetics

50. **Olstad EW, Nordeng HME**, Bjørk MH, Selmer K, **Gervin K**. Paternal valproate use and impact of shared genetic susceptibility on child neurodevelopment. *Sci Rep*. 2025 Nov 7;15(1):39033. doi: 10.1038/s41598-025-23377-1. PMID: 41203668; PMCID: PMC12595016.
51. **Carson AC, Zidan M, Olstad EW, Gervin K**, Galesloot TE, Scholte I, Ystrom E, **Nordeng H, van Gelder MMHJ**. Genetically Informed Research Designs in Perinatal Pharmacoepidemiology: A Methodological Overview. *In revision*.
52. Kinge-Rasmussen M, **Olstad EW**, Bjørk MH, **Nordeng HME**, Tan MMX, **Gervin K**, Selmer KK. Genetic susceptibility for neurodevelopmental disorders in children born to women with epilepsy. *Submitted*.

COVID-19/Vaccines

53. Hallberg A, Aakjaer M, Aaltonen K, Andersen M, Pedersen E, Hajiebrahimi M, **Nordeng H**, Nyberg F, Samuelsen PJ, Wettermark B. Epidemiological outcomes and policy implementation in the Nordic countries during the COVID-19 pandemic. *Arch Public Health*. 2025 Feb 20;83(1):46.
54. López-Güell K, Català M, Dedman D, Duarte-Salles T, Kolde R, López-Blasco R, Martínez Á, Mercier G, Abellan A, Arinze JT, Burkard T, Burn E, Cuccu Z, Delmestri A, Delseny D, Khalid S, Kim C, Kim JW, Kostka K, Loste C, Mayer MA, Meléndez-Cardiel J, Mercadé-Besora N,

- Mosseveld M, Nishimura A, **Nordeng HM**, Oyinlola JO, Paredes R, Pérez-Crespo L, Pineda-Moncusí M, Ramírez-Anguila JM, **Trinh NTH**, Uusküla A, Valdivieso B, Prieto-Alhambra D, Xie J, Mateu L, Jödicke AM. Clusters of post-acute COVID-19 symptoms: a latent class analysis across 9 databases and 7 countries. *J Clin Epidemiol*. 2025 Jun 13;185:111867. doi: 10.1016/j.jclinepi.2025.111867. Epub ahead of print. PMID: 40517846.
55. Barbieri E, **Trinh NTH**, Di Chiara C, Corrao G, Boracchini R, Rosa E, Liberati C, Donà D, **Lupattelli A**, Giaquinto C, Cantarutti A. Impact of Prior SARS-CoV-2 Infection on COVID-19 Vaccine Effectiveness in Children and Adolescents in Norway and Italy. *Vaccines (Basel)*. 2025 Jun 27;13(7):698. doi: 10.3390/vaccines13070698. PMID: 40733675; PMCID: PMC12298735.
 56. Zwiers LC, Grobbee DE, Schneijdenberg R, Baljé C, St Laurent S, Esposito DB, Zhu L, Urdaneta VV, Emilebacker M, Weibel D, Villalobos F, Bissacco CA, Urchueguía Fornes A, Carreras-Martínez JJ, **Desalegn AA**, **Lupattelli A**, Wang L, Wheler J, Ehrenstein V, Morris D, Fry C, Jansen M, Goodale BM, Ong DSY. Clinical Course, Outcomes, and Risk Factors of Myocarditis and Pericarditis Following Administration of mRNA-1273 Vaccination: A Protocol for a Federated Real-World Evidence Vaccine Safety Study Using Data from Five European Data Sources. *Vaccines (Basel)*. 2025 Jul 16;13(7):755. doi: 10.3390/vaccines13070755. PMID: 40733732; PMCID: PMC12299067.
 57. GBD 2023 Vaccine Coverage Collaborators (**Desalegn A**). Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023. *Lancet*. 2025 Jul 19;406(10500):235-260. doi: 10.1016/S0140-6736(25)01037-2. Epub 2025 Jun 24. PMID: 40578370; PMCID: PMC12338332.
 58. **Zidan M**, **Trinh NTH**, **Desalegn A**, Smith LH, **van Gelder MMHJ**, **Nordeng H**, **Lupattelli A**. BNT162b2 mRNA COVID-19 vaccine effectiveness in pregnancy: Emulating trial NCT04754594 using observational data from Norwegian health registries. *Vaccine*. 2025 Nov 6;68:127908. doi: 10.1016/j.vaccine.2025.127908. Epub ahead of print. PMID: 41202612.
 59. de Bruin O, Maisonneuve E, Hurley E, **Nordeng HME**, Bérard A, Sheehy O, Kaul P, Shinde MU, Cosgrove A, Lyons JG, Messenger-Jones E, Kempner ME, Toh S, Hua W, Hernández-Muñoz JJ, Sahin L, Cesta CE, Hägg D, Gini R, Paoletti O, Poblador-Plou B, Jordan S, Rodríguez-Bernal CL, Sánchez-Sáez F, Lassalle R, Bernard MA, Ahmadizar F, Favre G, Panchaud A, Bloemenkamp KWM, Plueschke K, de Vries C, Siiskonen SJ, Sturkenboom MCJM; CONSIGN Collaboration Group. Adverse outcomes among pregnant women with COVID-19 according to hospitalization status: A prospective individual participant data meta-analysis in Europe and North America. *Int J Gynaecol Obstet*. 2025 Dec 15. doi: 10.1002/ijgo.70694. Epub ahead of print. PMID: 41392882.
 60. de Bruin O, Maisonneuve E, Hurley E, **Nordeng HME**, Bérard A, Sheehy O, Kaul P, Shinde MU, Cosgrove A, Lyons JG, Messenger-Jones E, Kempner ME, Toh S, Hua W, Hernández-Muñoz JJ, Sahin L, Cesta CE, Hägg D, Gini R, Paoletti O, Poblador-Plou B, Jordan S, Thayer D, Rodríguez-Bernal CL, Sánchez-Sáez F, Lassalle R, Bernard MA, Alsina E, Ahmadizar F,

- Favre G, Panchaud A, Bloemenkamp KWM, Plueschke K, de Vries C, Siiskonen SJ, Sturkenboom MCJM; CONSIGN Collaboration Group. Medications Used Among Nonhospitalized Pregnant Women With COVID-19: A Prospective Individual Patient Data Meta-Analysis in Europe and North America. *Pharmacoepidemiol Drug Saf.* 2026 Jan;35(1):e70303. doi: 10.1002/pds.70303. PMID: 41449787; PMCID: PMC12741507.
61. Burkard T, Lopez-Guell K, Catala M, Burn E, Delmestri A, Khalid S, Joedicke AM, Dedman D, Oyinlola JO, Abellan A, Crespo LP, Mercade-Besora N, Duarte-Salles T, Prieto-Alhambra D, Arinze J, Mosseveld M, Kolde R, Melendez J, Lopez-Blasco R, Martinez A, Valdivieso B, Delseny D, Mercier G, Kim C, Kim J, Kostka K, Ramirez-Anguila JM, Mayer MA, **Trinh NTH, Nordeng HME**, Paredes R, Uuskula A, Nishimura A, Loste C, Mateu L, Xie J. The risks of autoimmune and inflammatory post-acute COVID-19 conditions: A network cohort study in six European countries, the US, and Korea. *Submitted.*
 62. Alcalde-Herraiz M, Du M, Sanchez-Parada A, Duarte-Salles T, Palomar-Cros A, Giuliadori A, Delmestri A, **Hayati S, Trinh NTH, Nordeng H**, Prieto-Alhambra D, Catala M, Prats-Urbe A. The effectiveness of HPV vaccination against invasive cervical cancer and related pre-cancerous lesions: a multinational target trial emulation study. *Submitted.*
 63. **Trinh N**, Fukasawa T, Yanai T, Okura T, Takayama A, Sakai T, Reiakvam O, Kawakami K, **Nordeng H**. Pediatric outpatient antibiotic utilization patterns before, during and after the COVID-19 pandemic: a cross-national study using data from Norway and Japan. *Submitted.*
 64. Giorcelli a, Rigamonti V, Rocchi M, Ieva F, Torri V, Cavinato L, Morris SK, Cotugno N, Palma P, **Nordeng H, Trinh NTH**, Dona D, Giaquinto C, Chiara CD, Cantarutti A. Dynamics of Influenza Vaccination and Respiratory Virus Infections in Children: A Multistate Model Approach. *Submitted.*
 65. Duarte-Salles T, Besora NM, Raventós B, Trinh NTH, Li H, Hayati S, Giuliadori A, Burkard T, Burn E, Català M, Prieto-Alhambra D, Morales DR, Nyberg F, **Nordeng HME**. Effectiveness of COVID-19 mRNA primary and booster vaccination against infection and hospitalisation during pregnancy: a target trial emulation and meta-analysis of data from four European countries. *Submitted.*
 66. Sørup S, Rasmussen TB, Fry C, Villalobos F, **Zidan M**, Buranelli C, van Willigen M, Morris D, **Lupattelli A**, Bissacco CA, Wang L, Alsema A, Lane S, **Desalegn A**, Roy D, Far M, Esposito D, St Laurent S, Zhu L, Urdaneta V, Emilebacker M, Sørensen HT, Ehrenstein V. Safety assessment of mRNA-1273 COVID-19 vaccine based on 38 adverse events of special interest: a population-based regulator-mandated post-authorization safety study in Denmark, Norway, Spain, and the United Kingdom using cohort and self-controlled designs. *Submitted.*

Other Publications

67. Radoš SN, Ganho-Ávila A, Rodriguez-Muñoz MF, Bina R, Kittel-Schneider S, Lambregtse-van den Berg MP, Lega I, **Lupattelli A**, Sheaf G, Skalkidou A, Uka A, Uusitalo S, Bosteels-Vanden Abeele L, Moura-Ramos M. Evidence-based clinical practice guidelines for

- prevention, screening and treatment of peripartum depression. *Br J Psychiatry*. 2025 Jun 26;1-12. doi: 10.1192/bjp.2025.43. Epub ahead of print. PMID: 40566968.
68. Beslay M, Geissbühler Y, Beau AB, Messina D, Benevent J, Ballardini E, Barrachina-Bonet L, Cavero-Carbonell C, Coldea A, García-Villodre L, Geldhof A, Gini R, Hellwig K, Jordan S, Leinonen MK, Lopez-Leon S, Manfrini M, Martikainen V, Mitter VR, Neville AJ, **Nordeng H**, Puccini A, Vukusic S, Morris JK, Damase-Michel C. Identifying multiple sclerosis in women of childbearing age in six European countries: a contribution from the ConcePTION project. *Eur J Epidemiol*. 2025 Jul 18. doi: 10.1007/s10654-025-01264-3.
 69. Vallejo-Yagüe E, de Vries ST, La Parra-Casado D, Gardarsdóttir H, Faquetti ML, van Valkengoed I, Aubrun E, Douros A, Guedes S, Martinez-De La Torre A, Wested J, Ochi T, Schumacher Dimech AM, Clair C, Mehta I, Ida F, Soriano Gabarró M, Korzh O, Martínez-González M, Maso A, Clamote Rodrigues D, Ndem-Galbert JR, Korjagina M, Goswami S, Moga DC, Marcus AF, **Nordeng H**. Advancing Health Equity in Europe: Explore, Tailor, Implement, and Evaluate (ETIE)-A Framework of Diversity and Fairness in Pharmacoepidemiologic Research. *Pharmacoepidemiol Drug Saf*. 2025 Jul;34(7):e70175.
 70. Hämeen-Anttila K, Almarsdóttir AB, Volmer D, **Björnsdóttir I**, Källemark Sporrang S. An ideological playground? Changes in community pharmacy ownership - a case study from four Nordic and Baltic countries. *J Pharm Policy Pract*. 2025 Oct 6;18(1):2564825.
 71. **Kadir L**, Bjørknes MR, Waaseth M, Holst L, Nilsen MK, Foss C, **Granås AG**. Pharmacy Stories: Creating a digital learning platform on pharmacy history. *In revision*.
 72. Raffea Y, Sandve GK, Braa K, **Nordeng H**. The impact of climate change on medication use and the role of medication data in climate-health analysis: A systematic literature review and stakeholder interviews. *Submitted*.
 73. Adolescent hormonal contraceptive use, depression, and brain development: An integrative review and considerations for future research. MacSweeney N, Dumoulin T, Aksnes ER, Barth C, Crestol A, Heller C, **Nordeng H**, Toende YJ. *Submitted*.

National publications

National guidelines

74. **Nordeng H**, Jettestad M, Sitras V. Legemiddelbruk i svangerskapet og ammeperioden (2020). Nasjonal metodebok for legevaktmedisin. *In revision*.
75. Jettestad M, Eide J, **Nordeng H**. Rus og legemiddelmisbruk i svangerskap (2020). Nasjonal metodebok for legevaktmedisin. *In revision*.

Norwegian publications

76. Ruths S, **Granås AG**, Spigset O, Ranhoff AH, Bakken MS. Verktøy for bedre legemiddelbehandling hos eldre. *Tidsskr Nor Laegeforen*. 2025 Feb 25;145(3). Norwegian.
77. Ystrøm E, **Nordeng H**. Paracetamol i svangerskapet. *Tidsskr Nor Laegeforen*. 2025 Nov 11;145. Norwegian.

Conference presentations (incl. submitted abstracts)

1. **Josendal AV, Granas AG**, Bergmo TS. Changes in prescribed medications after the introduction of an electronic prescribing system for patients with multidose drug dispensing [Poster presentation]. European Drug Utilization Conference (EuroDURG) 2025: Bridging Data, Policy & Patients in Drug Utilization Research. Uppsala, Sweden, 1–4 July 2025.
2. **Granas AG, Josendal AV**, Søbakk OM, Eek AK. NOAC in patients with multidose drug dispensing: Drug interactions, concomitant use of anticholinergic or fall risk increasing drugs [Poster presentation]. European Drug Utilization Conference (EuroDURG) 2025: Bridging Data, Policy & Patients in Drug Utilization Research. Uppsala, Sweden, 1–4 July 2025.
3. Klinkaite K, Matulaitiene R, Braticikoviene N, **Granas AG**. Pharmacy Labels and Written Information on Medication Adherence: PLIMA study protocol [Poster presentation]. European Drug Utilization Conference (EuroDURG) 2025: Bridging Data, Policy & Patients in Drug Utilization Research. Uppsala, Sweden, 1–4 July 2025.
4. **Granas AG**, Andric M, Stojanovic J, Gamlem AI, Toreid B. Improving the Cloud solution, Cassette, and Dispenser for an e-Dosette – a Design Thinking approach [Poster presentation]. European Drug Utilization Conference (EuroDURG) 2025: Bridging Data, Policy & Patients in Drug Utilization Research. Uppsala, Sweden, 1–4 July 2025.
5. Peker DS, Nyberg F, Li H, **Trinh N, Nordeng H**, Andersen M. COvid-19 among HEalth caRE professionals in the Nordic CountriEs (COHERENCE II): Methods for harmonizing data, study design and analyses in Denmark, Norway and Sweden [Poster presentation]. European Drug Utilization Conference (EuroDURG) 2025: Bridging Data, Policy & Patients in Drug Utilization Research. Uppsala, Sweden, 1–4 July 2025.
6. Weibel D, de Luise C, Cid Royo A, Ryan O, Vaz T, Aguado J, Marsal J, García de Albéniz X, Weinrib R, Palà E, Haugh M, Poblador B, Gimeno-Miguel A, Santos-Mejías A, Marconi E, Barbieri E, Stona L, Lysen T, Gaspersz J, Overbeek J, Herings R, Roy D, Lane S, Fry C, Morris D, Hyeraci G, Girardi A, **Lupattelli A, Desalegn A**, Villalobos F, Bissacco CA, Rubino H, Sturkenboom MCJ, Arana A. 2024 interim results from the VAC4EU post-authorisation safety study (PASS) for the Pfizer-BioNTech COVID-19 vaccine (Comirnaty®) in Europe [Poster presentation]. 41st Annual Meeting of the International Society for Pharmacoepidemiology. Washington D.C., U.S.A., 22–26 August 2025.
7. Zwiers L, van der Velden F, **Desalegn AA, Zidan M**, Jansen M, Grobbee D, Ong D. Risk factors for myocarditis/pericarditis following mRNA-1273 vaccination: Interim analysis of a VAC4EU case-cohort study [Poster presentation]. 41st Annual Meeting of the International Society for Pharmacoepidemiology. Washington D.C., U.S.A., 22–26 August 2025.
8. Zwiers L, van der Velden F, **Zidan M, Desalegn AA**, Jansen M, Grobbee D, Ong D. Clinical course of myocarditis/pericarditis cases following mRNA-1273 vaccination compared to cases not following COVID-19 vaccination: Interim analysis of a VAC4EU cohort study

- [Poster presentation]. 41st Annual Meeting of the International Society for Pharmacoepidemiology. Washington D.C., U.S.A., 22–26 August 2025.
9. Mercadé-Besora N, Raventós B, **Trinh NTH**, Li H, **Hayati S**, Burkard T, Burn E, Català M, **Lupattelli A**, Giuliadori A, Prieto-Alhambra D, Morales D, Nyberg F, **Nordeng H**, Salles TD. Effectiveness of booster (third-dose) COVID-19 vaccination during pregnancy: a target trial emulation study using 4 European databases [Poster presentation]. 41st Annual Meeting of the International Society for Pharmacoepidemiology. Washington D.C., U.S.A., 22–26 August 2025.
 10. Ehrenstein V, **Zidan M**, Fry C, Villalobos F, Buranelli C, **Lupattelli A**, Morris D, Far M, **Desalegn A**, Lane S, Bissacco CA, Roy D, Fang XT, Wang L, Esposito DB, St Laurent S, Zhu L, Urdaneta V, Emilebacker M, Sørup S. Monitoring safety of Moderna COVID-19 vaccines in pregnancy: A multi-database study in Denmark, Norway, Spain, and the United Kingdom. A regulator-mandated post-authorisation safety study in the VAC4EU network (EUPAS44450) [Poster presentation]. 41st Annual Meeting of the International Society for Pharmacoepidemiology. Washington D.C., U.S.A., 22–26 August 2025.
 11. Sørup S, Rasmussen TB, Fry C, Villalobos F, **Zidan M**, van Willigen M, Morris D, **Lupattelli A**, Bissacco CA, Wang L, Alsema A, Lane S, **Desalegn A**, Roy D, Far M, Esposito DB, St Laurent S, Zhu L, Urdaneta V, Emilebacker M, Sørensen HT, Ehrenstein V. Monitoring the Safety of mRNA-1273 COVID-19 Vaccine in the General Population: Results of a Regulator-mandated Post-authorisation Safety Study in Denmark, Norway, Spain, and the United Kingdom (EUPAS44273) [Podium/oral presentation]. 41st Annual Meeting of the International Society for Pharmacoepidemiology. Washington D.C., U.S.A., 22–26 August 2025.
 12. Alcalde-Herraiz M, Du M, Sanchez-Parada A, Duarte-Salles T, Palomar-Cros A, Giuliadori A, Delmestri A, **Hayati S**, **Trinh NTH**, **Nordeng H**, Prieto-Alhambra D, Catala M, Prats-Urbe A. The effectiveness of HPV vaccination against invasive cervical cancer and related pre-cancerous lesions: a multinational target trial emulation study [Poster presentation]. 41st Annual Meeting of the International Society for Pharmacoepidemiology. Washington D.C., U.S.A., 22–26 August 2025.
 13. Saura-Lazaro A, Alcalde-Herraiz M, Burn E, Delmestri A, Omulo H, Møldrup C, Bräuner E, Bruun S, Jacob J, Norris R, Vivirito A, Harms A, Vuković J, Pristaš I, Jurčević A, Čavlina M, Jezidžić De A, Ivanko P, Hayati S, **Trinh NTH**, **Nordeng H**, Duarte-Salles T, Palomar-Cros A, Giuliadori A, Prats-Urbe A. DARWIN EU® – Characterising Clinically Recognised Hypertrophic Cardiomyopathy in five European Countries: A Descriptive Analysis Using Real-World Data [Poster presentation]. 41st Annual Meeting of the International Society for Pharmacoepidemiology. Washington D.C., U.S.A., 22–26 August 2025.
 14. Willis S, **van Gelder M**, **Wood M**, **Nordeng H**, Dareng E, Rivero E, Layton D, Bliddal M, Broe A – *on behalf of The Medications in Pregnancy and Lactation (MiPAL) consensus working group*. Enhancing Pregnancy Drug Safety Studies: Expert Consensus on Methods and Definitions [Poster presentation]. 41st Annual Meeting of the International Society for Pharmacoepidemiology. Washington D.C., U.S.A., 22–26 August 2025.

15. Meng LC, **van Gelder MMHJ**, **Lupattelli A**, Chuang HM, Lai HY, Chen LK, Hsiao FY, **Nordeng HME**. Paternal exposure to valproate and risk of neurodevelopmental disorders in children – a nationwide registry-based study in Norway [Podium/oral presentation]. 41st Annual Meeting of the International Society for Pharmacoepidemiology. Washington D.C., U.S.A., 22–26 August 2025.
16. Vallejo-Yague E, Dickinson H, Torre AM, Gonzalez MM, Ochi T, Vries ST, **van Gelder MMHJ**, **Nordeng HME**. Seeking the roadmap: Incorporating menstruation and menopause into pharmacoepidemiology research [Symposium/workshop]. 41st Annual Meeting of the International Society for Pharmacoepidemiology. Washington D.C., U.S.A., 22–26 August 2025.
17. Li X, Burn E, Alhambra DP, Uribe AP, Delmestri A, Mosseveld M, Salles TD, **Nordeng HME**, Mendex A, **Hayati S**, **Trinh NTH**, Cros AP, Giuliadori A, Verhamme K, Jadhav G, Brash J, Lazaro AS. DARWIN EU® - Background incidence rates of selected vaccine adverse events of special interest (AESIs) in Europe [Poster presentation]. 41st Annual Meeting of the International Society for Pharmacoepidemiology. Washington D.C., U.S.A., 22–26 August 2025.
18. Raventós B, Mercadé-Besora N, **Trinh NTH**, **Hayati S**, Burkard T, Burn E, Català M, **Lupattelli A**, Giuliadori A, Prieto-Alhambra D, Morales D, Nyberg F, **Nordeng H**, Salles TD. Effectiveness of COVID-19 primary vaccination during pregnancy: a target trial emulation study using 4 European countries [Poster presentation]. 41st Annual Meeting of the International Society for Pharmacoepidemiology. Washington D.C., U.S.A., 22–26 August 2025.
19. Kinge-Rasmussen MM, Selmer KK, **Gervin K**, Bjørk MH, **Nordeng HME**, Tan M, **Olstad EW**. Genetic Susceptibility for Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorders in Children Born to Women with Epilepsy [Poster presentation]. 36th International Epilepsy Congress. Lisbon, Portugal, 30 August–3 September 2025.
20. Carlsen SE, Hargreave M, Jarden E, Hemmingsen CH, Schmidt L, Hjorth S, Leinonen MK, Nörby M, Mørch LS, Kjær SK, **Nordeng H**. Maternal hormonal contraception use and the risk of childhood cancer: A systematic review and meta-analysis [Poster presentation]. Association of the Nordic Cancer Registries (ANCR) symposium. Reykjavik, Iceland, 3–5 September 2025.
21. **van Gelder MMHJ**, **Zugic M**, van Nederveen-Bendien SA, Bliddal M, Ceulemans M, Cleary B, Dyekær Egsgaard S, Marin B, O'Shaughnessy F, **Nordeng H**, Merkus PJFM. Asthma medication use before and during pregnancy: guidelines versus multinational practice [Poster presentation]. 2025 Annual meeting of the European Network of Teratology Information Service (ENTIS). Thessaloniki, Greece, 11–14 September 2025.
22. Havnen GC, Adan NH, Topalovic J, Eek AK, **Nordeng H**. ADHD During Pregnancy and the First Postpartum Year: A Survey Among Norwegian Women [Poster presentation]. 2025 Annual meeting of the European Network of Teratology Information Service (ENTIS). Thessaloniki, Greece, 11–14 September 2025.

23. **Desalegn AA, Zidan M, Trinh NTH, Lupattelli A, Nordeng H.** Trimester-Specific Effects of SARS-CoV-2 Infection on Placental and Fetal Outcomes: A Norwegian Cohort Study [Poster presentation]. 3rd European Perinatal and Paediatric Epidemiology Conference (EPPEC). Oslo, Norway, 15-16 September 2025.
24. **van Gelder MMHJ, Hsiao FY, Nordeng H.** Nordic-Asia Pacific collaboration in real-world evidence studies: lessons learned and opportunities for future research networks [Workshop]. ISPOR Real-World Evidence Summit 2025. Tokyo, Japan, 28-30 September 2025.
25. Saura-Lazaro A, Alcalde-Herraiz M, Burn E, Delmestri A, Omulo H, Møldrup C, Bräuner E, Bruun S, Jacob J, Norris R, Vivirito A, Harms A, Vuković J, Pristaš I, Jurčević A, Čavlina M, Jezidžić De A, Ivanko P, Hayati S, Trinh NTH, **Nordeng H**, Duarte-Salles T, Palomar-Cros A, Giuliadori A, Prats-Urbe A. DARWIN EU® – Characterising Clinically Recognised Hypertrophic Cardiomyopathy in five European Countries: A Descriptive Analysis Using Real-World Data [Poster presentation]. ISPOR Real-World Evidence Summit 2025. Tokyo, Japan, 28-30 September 2025.
26. Solórzano M, Riefolo F, Durán C E, Gini R, Messina D, Roberto G, Pazos I, Luxi N, Riera-Arnau J, Mohammadi S, Vilaseca A, Morton K, Barbieri E, Sturniolo G, Chiusaroli L, Riveiro-Barciela M, Davies M, Zafon C, Viapiana O, Rotta D, Borrueal N, Dhanda S, Roy D, Ingrassiotta Y, Carollo M, Erra A, Lopez-Lasanta M, Rossini M, Bellitto C, Villalobos F, **Nordeng H, Zidan M**, Castillo-Cano B, Martín-Merino E, Carreras J J, Urchueguía-Fornes A, Souverein P, Jové J, Bernard M A, Sturkenboom M. Flares Of Ten Autoimmune Diseases: Clinical Definitions, Operational Algorithms, And Background Incidence Rates In Seven European Electronic Healthcare Data Sources [Poster presentation]. ISPE LATAM Pharmacoepidemiology Congress. Sao Paulo, Brazil, 9-11 October 2025. *Submitted*.
27. Mohammadi S, Durán CE, Gini R, Messina D, Riefolo F, Riera J, Hoxha V, Pazos I, Ehrenstein V, **Nordeng H**, Stona L, Vo T, Tolppanen AM, Roberto G, Sturkenboom MA. European Framework for Post-Authorisation Vaccine Safety Monitoring Using Real-World Data (SAFETY-VAC project): A multi-database cohort study in seven countries [Poster presentation]. Annual Meeting of the International Society for Pharmacoepidemiology. Cairo, Egypt, 24–27 October 2025.
28. Roberto G, Gini R, Messina D, Durán Salinas C, Sturkenboom M, Riera-Arnau J, Riefolo F, Pazos I, Villalobos F, Solórzano M, Carreras J.J., Urchueguía-Fornes A, **Nordeng H**, Castillo-Cano B, Borrueal N. Impact of data prompts on identifying ulcerative colitis patients and flares in four European healthcare databases [Poster presentation]. Annual Meeting of the International Society for Pharmacoepidemiology. Cairo, Egypt, 24–27 October 2025.
29. **Zidan M, Trinh NTH, Desalegn A**, Smith LH, **van Gelder MMHJ, Nordeng H, Lupattelli A.** Comirnaty Vaccine Effectiveness in Pregnancy: Emulating Trial NCT04754594 Using Observational Data from Norwegian Health Registries [Poster presentation]. Annual Meeting of the International Society for Pharmacoepidemiology. Cairo, Egypt, 24–27 October 2025.

30. Meng LC, **van Gelder MMHJ**, Chuang HM, Lai HY, Chen LK, Hsiao FY, **Nordeng HME**. Valproate Use by Fathers During Spermatogenesis and Risk of Neurodevelopmental Disorders in Children: A Cross-National Study from Norway and Taiwan [Poster presentation]. Annual Meeting of the International Society for Pharmacoepidemiology. Cairo, Egypt, 24–27 October 2025.
31. Acar MS, **Nordeng H, Hayati S, Trinh N**, Moeller C, Candore G, Dinkel-Keuthage C, Manlik K, Pineda-Moncusi M. Real-world treatment patterns for heavy menstrual bleeding in the United States and Norway: A European Health Data and Evidence Network study [Poster presentation]. American Society for Reproductive Medicine (ASRM) 2025 Scientific Congress & Expo. San Antonio, Texas, U.S.A., 25-29 October 2025.
32. **Zidan M, Trinh NTH, Desalegn A**, Smith LH, **van Gelder MMHJ, Nordeng H, Lupattelli A**. Comirnaty Vaccine Effectiveness in Pregnancy: Emulating Trial NCT04754594 Using Observational Data from Norwegian Health Registries [Poster presentation]. 31st Norsk Forening for Epidemiologi Conference. Bergen, Norway, 29-30 October 2025.
33. **Kadir L**, M Einen, H. U. Irgens, J. C. Bergmann, G-T. L. Sørland, **A. Mulac, A. G. Granås**. Assessing medication safety culture in Norwegian pediatric wards [Poster presentation]. Farmasidagene. Oslo, Norway, 13-14 November 2025.
34. **Björnsdottir I**, Christensen S, Lauritzen F, Gjelstad A. Action research on athletes' need for information to avoid inadvertent doping [Poster presentation]. Farmasidagene. Oslo, Norway, 13-14 November 2025.
35. **Carson A, Trinh N, Nordeng H**, Smew A, Cesta C. Antenatal antidepressant use and subsequent offspring type 1 diabetes in Norway and Sweden [Oral presentation]. NorPEN 2025. Uppsala, Sweden, 19-21 November 2025.
36. **Nordeng H, Hayati S, van Gelder M**. Identification of pregnancies in real-world data: head-to-head comparison of three algorithms [Oral presentation]. NorPEN 2025. Uppsala, Sweden, 19-21 November 2025.
37. **Nordeng H, van Gelder M**. Impact of follow-up time on the identification of neurodevelopmental disorders in Norwegian children in real-world registry data [Poster presentation]. NorPEN 2025. Uppsala, Sweden, 19-21 November 2025.

Lectures

International external lectures

1. **Trinh N**. Norwegian data sources for RWE research. Presentation for MedEngine team. Finland. 18 March 2025.
2. **Granås AG**. eHealth and adherence enhancing technologies. CBIOS - Universidade Lusófona's Research Center for Biosciences & Health Technologies. Lisbon, Portugal, 20 March 2025.
3. **Kadir L**. Medication management in Norwegian pediatric wards. Lasten sairaalafarmasistit yhteistyöpalaveri. Helsinki, Finland, 29 April 2025.

4. **Kadir L** (organizer and host), Rautamo M (presenter). Implementing 3D printing of pediatric drugs – latest update in Europe. Digital Meeting, 06 May 2025.
5. **van Gelder M**. Drug safety in pregnancy and lactation. 21st European Society for Developmental Perinatal and Paediatric Pharmacology Congress. Nijmegen, The Netherlands, 25-27 June 2025.
6. **Nordeng H**. ADHD Medications in Pregnancy & Breastfeeding (state of the art lecture). 36th ENTIS Conference. Thessaloniki, Greece, 13 September 2025.
7. Camanni M. Association of Prenatal Exposure to Triptans, Alone or Combined With Other Migraine Medications, and Neurodevelopmental Outcomes in Offspring. Women's Neurology programs at the Universities of Harvard, Toronto and Pittsburgh, USA. Digital Meeting, 19 September 2025.
8. **Granås AG**. The Menopause - facts and fiction. Lunch with Drugs Seminar. Vilnius, Lithuania, 19 September 2025.
9. **Granås AG**. Medicine Accessibility in Norway, Challenges and initiatives before, during and after the Covid-19 pandemic. 40th anniversary of the Congress of the Lithuanian Pharmaceutical Association. Kaunas, Lithuania, 20 September 2025.
10. **Granås, AG**. Integrating two Coursera courses on Patient perspectives on medicine use from the University of Copenhagen into the FARM5000 Preparation Course for Master`s thesis in Pharmacy at the Department of Pharmacy, University of Oslo: A blended learning approach – course structure, experiences and suggestions for future development. Seminar for the Centre for Online and Blended Learning. Copenhagen, Denmark, 25 September 2025.
11. **Nordeng H**. Nordic-Asia Pacific Collaboration in Real-World Evidence Studies: Lessons Learned and Opportunities for Future Research Networks. ISPoR Real World Evidence Summit. Tokyo, Japan, 29 September 2025.
12. **Nordeng H**. Panel discussion, Pharmacovigilance: Are We Ready for the Next Era? European Medicines Agency. 26 November 2025.

National external lectures

13. **Nordeng H**. Real-World Evidence on Pharmaceuticals for Regulatory Purpose in the EU – Capitalizing on Norwegian health registry data in large European initiatives. Norway Life Science Conference. Oslo, Norway, 11 February 2025.
14. **Granås AG**. Hormonell ommøblering i overgangsalderen. Årsmøte Diabetesforbundet. Oslo, Norway, 11 February 2025.
15. **Granås AG**. Innovasjon av e-dosetten Mobili – utvikling av app, dispenser og kassett ved hjelp av Design Thinking metode. Vingmed Forum. Gardermoen, Norway, 11-12 March 2025.
16. **Nordeng H**. NSAIDs in pregnancy – what should national clinical guidelines say? Teaching for obstetricians at Rikshospitalet. Oslo, Norway, 3 April 2025.
17. **Nordeng H**. Vaccination in Pregnancy – studies at PharmaSafe. Vaksineseminar at the Norwegian Institute of Public Health. Oslo, Norway, 13 May 2025.

18. **Nordeng H.** From Data to Impact: Harnessing Norwegian Health Data for Safe Medications and Sustainable Women's Health. MN Sustainability seminar. Asker, Norway, 13 May 2025.
19. **Nordeng H.** Capitalizing on UIOs eInfrastructure to fill knowledge gaps about use and safety of medicine and vaccines. data@uio conference. Oslo, Norway, 10 June 2025.
20. **Granås AG.** Piller eller pilates? Hvordan møter vi best kvinnehelseutfordringene i eldre år? Kvinnehelseaften. Oslo, Norway, 12 June 2025.
21. **Nordeng H.** Kunstig intelligens og norske helsedata: hva er mulighetsrommet? Arendalsuka. Arendal, Norway, 13 August 2025.
22. **Nordeng H.** Et kvart århundre i endring – fra samfunnsfarmasi til farmakoepidemiologi. Samfunnsfarmasiens fremvekst og fremtid: fag- og emeritaseminar for professor Anne Elise Eggen. Tromsø, Norway, 31 October 2025.
23. **Nordeng H.** PRAC i praksis. Drug Safety Høstmøte, Legemiddelindustriforeningen. Oslo, Norway, 17 November 2025.
24. **Granås AG.** Eldre kvinner og medisinerer – Årlig legemiddelgjennomgang, Ås sanitetsforening. Ås, Norway, 1 September 2025.
25. **Granås AG.** Eldre kvinner og medisinerer – Årlig legemiddelgjennomgang, Vestby sanitetsforening. Vestby, Norway, 18 November 2025.
26. **Granås AG.** Resepten som kommunikasjonsmiddel mellom lege og apotek. Det Norske Medicinsk Selskab. Oslo, Norway, 10 December 2025.

Webinars

27. **Granås AG.** Eldre kvinner og legemidler. Innspilling av tre webinarer for Sanitetsforeningen. Digital Meeting, 2 December 2025.

Seminars organized

1. Pharmacovigilance Seminar, organized by **Nhung Trinh** and **Maren Olson** – Oslo, Norway, January 2025.
2. PharmaSafe Yearly Seminar, organized by **Hedvig Nordeng**, **Maren Olson**, et al. – Oslo, Norway, January 2025.
3. Norwegian-Danish Meeting, organized by **Hedvig Nordeng**, **Maren Olson**, et al. – Oslo, Norway, February 2025.
4. Fakta og mysterier i overgangsalderen, organized by **Anne Gerd Granås** and Ingunn Burud – Ås, Norway, April and May 2025.
5. Seminar on Pharmacoepidemiology and Public Health, organized by **Nhung Trinh** and **Maren Olson** – Oslo, Norway, September 2025.
6. Workshop on Causal Inference For Time-varying Exposures In Pregnancy Outcomes Research, organized by **Anteneh Desalegn** and **Maren Olson** – Oslo, Norway, September 2025.

7. OMOP Seminar 2025, organized by **Nhung Trinh** and **Maren Olson**– Oslo, Norway, September 2025.
8. ISPOR Summit, Symposium Nordic-Asia Pacific Collaboration in Real-World Evidence Studies: Lessons Learned and Opportunities for Future Research Networks, organized by **Hedvig Nordeng** and **Marleen van Gelder** – Tokyo, Japan, September 2025.

Guest researchers

1. **Takamasa Sakai**, Meijo University, Japan. Antipsychotics in pregnancy and the risk of adverse pregnancy outcomes - a nationwide study. April 2024-March 2025.
2. **Beatrice Cosentino**, University of Milano, Italy. Natural history of difficult-to-treat depression in adolescents from the first antidepressant trial (registry data in Norway). September 2024-January 2025.
3. **Theresa Burkard**, University of Oxford, UK. Validation of OMOP pregnancy algorithm on Norwegian Linked Health Registry data. December 2024- January 2025.
4. **Afshin Parvardeh**, University of Isfahan, Iran. Functional Data Analysis - Developing a new NVP curve. January 2025.
5. **Francesca Puddu**, University of Bologna, Italy. Utilizing Pharmaceutical Data as Indicators in Climate Health Analyses: A Systematic Literature Review. January 2025-April 2025.
6. **Eline Tommelein**, Vrije Universiteit, Belgium. ADHD medication use during pregnancy and breastfeeding. February 2025.
7. **Alessandro Riva**, University of Milano, Italy. Effect of antidepressant exposure during the early life-course on pubertal timing. March-August 2025
8. **Myrthe van de Meulenhof**, Radboud University, the Netherlands. Impact of a community pharmacist consultation on sick leave and healthcare utilization during pregnancy: the SafeStart intervention study. March-July 2025.
9. **Nguyen Tran Nam Tien**, Inje University College of Medicine, South Korea. Association of paternal drug exposure and offspring adverse drug reactions. April-September 2025.
10. **Erika Björkström Gram**, University of Southern Denmark, Denmark. Paracetamol use during pregnancy. October 2025.
11. **Emmanuel O Adewuyi**, Curtin University, Australia. Causal role of ASM-associated DNA methylation in child neurodevelopment: A two-step mendelian randomization study. November 2025-April 2026.

UiO:LifeScience summer students

1. **Peter Olteanu**. Enhancing Data Quality in Norwegian Registry Data. Main supervisor: **Hedvig Nordeng**. Co-supervisor: **Saeed Hayati**.
2. **Joana Slavinskaite**. Enhancing Data Quality in Norwegian Registry Data. Main supervisor: **Hedvig Nordeng**. Co-supervisors: **Nhung Trinh** and **Anteneh Desalegn**.
3. **Mina Karkhi**. Developing Simulated Datasets for Healthcare Research in Norway. Supervisors: **Anteneh Desalegn**, **Saeed Hayati**.

4. **Anastasia Bredenbrocki.** Developing Simulated Datasets for Healthcare Research in Norway. Supervisors: **Saeed Hayati, Anteneh Desalegn.**
5. **Thanh-Khiem Nguyen.** Utilizing pharmacovigilance data to explore safety concerns related to treatment combinations. Supervisor: **Nhung Trinh.**

Media coverage

1. [Viktige medisinar kan føra til kreft](#) forskning.no | Angela Lupattelli
2. [Slår medisin-alarm: - Kreftisiko](#) Dagbladet | Angela Lupattelli
3. [Norge har unike helsedata, men hvordan utnytte dem?](#) Farmatid | Hedvig Nordeng
4. [Norge har unike helsedata, men hvordan utnytte dem?](#) Farmatid | Hedvig Nordeng
5. [Studie: Medisin kobles til ADHD](#) Dagbladet pluss | Kristina Gervin
6. [Studie koblet diabetesmedisin til fosterskader: – -Dette tror vi ikke på i det hele tatt](#) forskning.no | Hedvig Nordeng
7. [UiO-forsker vil ha økt bruk av norske helsedata](#) Digi | Hedvig Nordeng
8. [Studien som koblet fars diabetesmedisin til fosterskader, fikk forskerne til å reagere med vantro.](#) Titan | Hedvig Nordeng
9. [Objektiv formidling eller forkledd reklame?](#) Forskerforum (via Retriever) | Anne Gerd Granås
10. [Faren avblåst: risikoen for misdanninger aukar ikkje om far brukar vanleg diabetesmedisin.](#) Diabetesfag | Hedvig Nordeng
11. [COVID-19-infeksjon, vaksiner og medisiner i svangerskapet](#) Senter for pandemi- og én-helseforskning | Hedvig Nordeng
12. [Ny algoritme fjernar tvil om sammenhengen mellom legemiddel og spontanabortar](#) forskning.no | Hedvig Nordeng
13. [Spillifiserer farmasiutdanningen - Farmatid](#) Farmatid | Mia C. N. Heimdal
14. [400 000 kroner til banebrytende morsmelkstudie om ADHD-medisiner](#) FAI | Hedvig Nordeng
15. [Medisinsk overgangsalder](#) MSD Oncocast | Anne Gerd Granås
16. [Kreftomsorg og kunstig intelligens \(KI\).](#) MSD Oncocast | Anne Gerd Granås
17. [Trump vil takle autisme med mindre paracet og mer B-vitamin](#) Titan | Hedvig Nordeng
18. [Bør gravide unngå paracetamol, slik Trump sier?](#) forskning.no | Hedvig Nordeng
19. [Kristi betalte 2.500 kroner for å beskytta sonen mot RS-virus](#) NRK | Hedvig Nordeng
20. [Bør gravide unngå paracetamol, slik Trump sier?](#) ABC Nyheter | Hedvig Nordeng
21. [Kvinner som debuterer med antidepressiva i svangerskapet, sluttar ofte raskt](#) Titan | Alexis Carson
22. [Kvinner som debuterer med antidepressiva i svangerskapet, sluttar ofte raskt](#) FAI | Alexis Carson
23. [Mye kunstig intelligens, antibiotikaresistens og norske farmasøyter på FIP](#) Farmatid | Ingunn Björnsdottir, Astrid Gjelstad

24. [Norske jordmødre: Ser ingen sammenheng mellom Paracet og autisme](#) Aftenposten | Hedvig Nordeng
25. [Klar for å finne på noe gøy i november? Her er en oversikt over noe av det som skjer](#) Vestby Avis | Anne Gerd Granås
26. [Hedvig Nordeng skal lede nytt konvergensmiljø](#) FAI | Hedvig Nordeng, Ole Andreas Økstad, Ragnhild Paulsen, Osman Gani, Josefine Eilsø Nielsen og Kristina Gervin
27. [Simulerer kliniske prøver på gravide med data frå helseregister](#) FAI | Mahmoud Zidan
28. [Reiser tvil om råd om fars bruk av epilepsimedisin før befruktning](#) FAI | Emilie Willoch Olstad
29. [FHI tilrår vaksine mot RS-virus for gravide og spedbarn](#) NRK | Hedvig Nordeng

Awarded research grants

Funding from regulators (2.36 MILL NOK), pharmaceutical industry (11.60 M NOK) and academic grants (15.85 M NOK), totaling 29.81 million NOK.

1. Hedvig Nordeng, Kristina Gervin, Jon Michael Gran. **UiO:Life Science Convergence Environment:** [UiO:RWE- Capitalizing on Norwegian Health Data for Rapid Generation of Real-World Evidence on Effectiveness and Safety of Pharmaceuticals.](#)
2. Rosa Catherine Gillespie Cheesman, Hedvig Nordeng, Alexandra Havdal, Nicolai Topstad Borgen, Krister Westlye Fjermestad, Astrid Marie Jorde Sandsør. **UiO:Life Science Convergence Environment:** [NeuroPathways- A Multidisciplinary Convergence Approach to Understanding and Supporting Neurodevelopmental Variability.](#)
3. Christian Krog Tamnes, Tilmann von Soest; Hedvig Nordeng, Claudia Barth; Tone Kristin Omsland, Anne Kveim Lie. **UiO:Life Science Convergence Environment:** [ContraMent- Hormonal contraceptives and mental health: A convergent, interdisciplinary approach.](#)
4. Hedvig Nordeng, Nhung Trinh, and Saeed Hayati. **Darwin EU Network:**
 - i. DARWIN Opioids DU study, 2025.
 - ii. DARWIN HIV pediatrics study, 2025.
 - iii. DARWIN Paediatric pulmonary arterial hypertension study, 2025.
 - iv. DARWIN Antipsychotics in children DU study, 2025.
 - v. DARWIN Paracetamol DU study, 2025.
 - vi. DARWIN ADHD DU study, 2025.
 - vii. DARWIN Sartans in children DU study, 2025.
 - viii. DARWIN Influenza vaccine effectiveness, 2025.
 - ix. DARWIN Cystic Fibrosis DU study, 2025.
 - x. DARWIN Characterisation CF patients, 2025.
 - xi. DARWIN Capturing Obesity in DARWIN EU, 2025.
 - xii. DARWIN Varicella Vaccine in DARWIN EU, 2025.
 - xiii. DARWIN Mother-child Linkage, 2025.
 - xiv. DARWIN Determinants for use of GLP1 receptor agonists DU study, 2025.

- xv. DARWIN Capturing suicidality and Depression, 2025.
- 5. Hedvig Nordeng, Nhung Trinh, and Saeed Hayati. **EHDEN Data Partner Network Cluster Headache Study**, 2024-2025.
- 6. Hedvig Nordeng. **EMAROC Vaccine Safety**, 2024-2026.
- 7. Anteneh A. Desalegn. **Pfizer projects**, 2025-2029.
 - a. Pfizer Protocol Development for RSV Vaccine Safety, 2025.
 - b. Pfizer Protocol Development for RSV Vaccine Effectiveness, 2025.
 - c. Pfizer RSV Vaccine Safety, 2025.
- 8. Anteneh Desalegn. **MedEngine Alzheimers Characterization in the Nordics**, 2025-2026.
- 9. Hedvig Nordeng, Nhung Trinh, Saeed Hayati, and Anteneh Desalegn. 5 **UiOLifeScience summer student projects**, 2025.
- 10. Alexis Carson. **Robert and Ella Wenzins Scholarship**, research stay at Karolinksa Institutet, 2025.
- 11. Nhung Trinh. **Åsgard Horizon Stipend**, organization of a seminar between Norwegian and French collaborators, 2025.
- 12. Hedvig Nordeng and Nhung Trinh (partners). **NordForsk**, Nordic networking activities to support knowledge development on the post-COVID condition (PCC), 2025.
- 13. Hedvig Nordeng and collaborators. **ADHD nettverk, Oslo Universitetssykehus**, Kan kvinner som bruker ADHD-legemidler amme? – kvantifisering av ADHD-midler i morsmelk, 2025-2026.
- 14. Dung Kim Tran (masterstudent). **Stiftelsen til fremme av norsk apotekfarmasi**, Innovasjonsprosjekt – Legemiddelhåndtering i hjemmesykepleien, 2025-2026.
- 15. Internationalization support from **UiO:Life Science**:
 - a. Anteneh A. Desalegn, research visit to Institute for Vaccine Safety (Johns Hopkins Bloomberg School of Public Health), 2025.
 - b. Alexis Carson. research stay at Karolinksa Institutet, 2025.
 - c. Mahmoud Zidan. research stay at Aarhus University, 2025.
 - d. Akhila Reddy. research stay at Radboud University, 2025.

Master's projects finished May/June

Internal Master's projects

- 1. **Jelena Popov**. Psychotropic treatment history and correlates of self-harm ideation at the time around pregnancy and childbirth among women with pre-existing mental illness. **Main Supervisors: Nhung Trinh**
- 2. **Noura Fanadi**. Understanding women perceptions and attitudes towards respiratory syncytial virus vaccination in pregnancy. Main Supervisors: **Hedvig Nordeng, Angela Lupattelli***.
- 3. **Zaklina Siminovic**. Understanding women and healthcare personnel perceptions and attitudes towards respiratory syncytial virus vaccination in pregnancy a mixed-method study. Main Supervisors: **Hedvig Nordeng, Angela Lupattelli***.

4. **Farhiya Sigaledatter** Muhamed Understanding women and healthcare personnel perceptions and attitudes towards respiratory syncytial virus vaccination in pregnancy a mixed-method study. Main Supervisors: **Hedvig Nordeng, Angela Lupattelli***.
5. **Ivana Antic.** Psychiatric safety of semaglutide and liraglutide in young adults and adolescents a pharmacovigilance disproportionality analysis. Main supervisors: **Angela Lupattelli*, Nhung Trinh**
6. **Alesia Finstad.** Patients`perspectives on polypharmacy in children with mental illnesses. Main Supervisor: **Nhung Trinh.** Co-supervisor: **Angela Lupattelli***
7. **Natasa Milojevic.** Patients`perspectives on polypharmacy in children with mental illnesses. Main Supervisor: **Nhung Trinh.** Co-supervisor: **Angela Lupattelli***
8. **Sara Bazaz.** Legemiddelbruk blant morsmelkdonorer på OUS - en klinisk kartleggingsstudie. Main Supervisor: **Hedvig Nordeng**
9. **Birgul Korkmaz** Legemiddelbruk blant morsmelkdonorer på OUS - en klinisk kartleggingsstudie. Main Supervisor: **Hedvig Nordeng**
10. **Omar Farooq Eedan Al-Obadi** Legemiddelbruk blant morsmelkdonorer på OUS - en klinisk kartleggingsstudie. Main Supervisor: **Hedvig Nordeng**
11. **Nacima Hashi Adan.** ADHD i svangerskap og ammeperiode. Main Supervisor: **Hedvig Nordeng**
12. **Jelena Topalovic.** ADHD i svangerskap og ammeperiode. Main Supervisor: **Hedvig Nordeng**
13. **Yara Raffea** Klimahelse - kan legemiddelbruk brukes som indikator I klimaanalyser. Main Supervisor: **Hedvig Nordeng**
14. **Salwa Abdelaziz Murad.** Ingen forskning uten meg! Pasientinvolvering i farmasøytisk forskning - hvordan og hvorfor? Main Supervisor: **Hedvig Nordeng**
15. **Marija Maljkovic:** Ingen forskning uten meg! Pasientinvolvering i farmasøytisk forskning - hvordan og hvorfor? Main Supervisor: **Hedvig Nordeng**
16. **Kristina Knisenko:** Hva er kulturen for legemiddelbruken I utvalgte idretter? - kvantitativ studie. Main Supervisor: **Ingunn Björnsdottir**
17. **Aleksandar Julija Kokorina.** Hva er kulturen for legemiddelbruken I utvalgte idretter? - kvantitativ studie. Main Supervisor: **Ingunn Björnsdottir**
18. **Maja Kokorina.** Utvikling av en ny astmamedisin-tjeneste, hvor vekten blir på å kommunisere om viktigheten av forebyggende. Main Supervisor: **Ingunn Björnsdottir**
19. **Thien-Kim Trinh.** Somatic and psychiatric comorbidity and complex medication use patterns among pregnant subjects with pre-existing mental illness. Main Supervisors: **Angela Lupattelli*, Nhung Trinh**

**Until Angela Lupattelli's passing in January 2025.*

External Master's projects

20. Milinkovic, Marija. Forskrivning av potensielt uhensiktsmessige legemidler hos personer med et antidemenslegemiddel. University of Bergen. Main supervisors: Ragnhild Djønnø Østerhus, **Anne Gerd Granås.**

21. Petrică Ioan Olteanu. Impact of Socioeconomic and Regional Factors on Gestational Diabetes Prevalence in Norway, 2018 – 2023: A Nationwide Linked Registry Study. Main supervisors: **Hedvig Nordeng, Saeed Hayati**.

Reports to the European Medicines Agency (EMA)

22. Durán CE, Gini R, Messina D, Castillo-Cano B, Roberto G, Riefolo F, Riera J, Mohammadi S, Pazos I, Sturkenboom M. Background incidence estimation of flares of pre-existing chronic diseases using pan-European electronic healthcare data sources. The Safety-Vac Consortium.

DARWIN studies for the European Medicines Agency (EMA)

Finalized

1. P2-C3-004: DARWIN EU® - [Effectiveness of Human Papillomavirus Vaccines \(HPV\) to prevent cervical cancer](#)
2. P3-C1-001: DARWIN EU® - [Characterising the use of JAK inhibitors in Europe: a Drug Utilisation Study](#)
3. P3-C1-018: DARWIN EU® - [Prevalence of hypertrophic cardiomyopathy \(HCM\) and obstructive hypertrophic cardiomyopathy \(oHCM\) in six European countries](#)
4. P3-C2-002: DARWIN EU® - [RR1 Drug Utilisation Study of prescription opioids](#)
5. P3-C3-001: DARWIN EU® - [Background incidence rates of selected vaccine adverse events of special interest \(AESIs\) in Europe](#)
6. P3-C3-008: DARWIN EU® - [Association of venous thromboembolism with non-steroidal anti-inflammatory drug use in women 15-49 years using hormonal contraceptives](#)
7. P4-C2-012: DARWIN EU® - [RR Childhood hypertension and sartans prescribing in children](#)

Ongoing

8. [P3-C1-020: DARWIN EU® - Use of antiretroviral therapies in paediatric patients](#)
9. [P3-C3-009: DARWIN EU® – Utilisation of commonly used benzodiazepines during pregnancy and the incidence of pregnancy losses](#)
10. [P3-C3-011: DARWIN EU® - Incidence, period prevalence, and characterisation of individuals with paediatric pulmonary arterial hypertension](#)
11. [P4-C1-008: DARWIN EU® - Drug utilisation study in individuals with cystic fibrosis in Europe](#)
12. [P4-C1-016: DARWIN EU® – Proof-of-concept: Preparedness for annual seasonal influenza vaccine effectiveness studies - Vaccine coverage and incidence of influenza-related outcomes](#)

13. P4-C2-002: [DARWIN EU® – Paracetamol prescribing and paracetamol overdose in Europe: a descriptive analysis of trends and patient characteristics](#)
14. P4-C2-003: [DARWIN EU® - Antipsychotic prescribing in children in Europe: a descriptive analysis of trends and patient characteristics](#)
15. P4-C2-006: [DARWIN EU® - Trends in utilisation of Attention-Deficit Hyperactivity Disorder \(ADHD\) Medications](#)
16. P4-C2-007: [DARWIN EU® - RR Characterisation of individuals with cystic fibrosis in Europe](#)
17. P4-C3-003: [DARWIN EU® - Encephalitis risk in pediatric varicella vaccine recipients](#)

PharmaSafe Members 2025

Name	Position
Hedvig Marie Egeland Nordeng	Professor/ head of research group
Anne Gerd Granås	Professor
Angela Lupattelli	Professor (deceased January 2025)
Ingunn Bjornsdottir	Associate professor
Maren Mackenzie Olson	Research coordinator
Marleen van Gelder	Senior researcher (40%)
Nhung Trinh	Senior researcher/lecturer (until 01.12.2025)
Anteneh Assefa Desalegn	Senior researcher
Kristina Gervin	Senior researcher (10%)
Saeed Hayati	Researcher
Emilie Willoch Olstad	Post doc
Milica Zugic	PhD student (maternity leave)
Akhila Srinivas Reddy	PhD student
Alexis Christine Carson	PhD student
Liv Vidas	PhD student
Lavin Kadir	PhD student
Mahmoud Zidan	PhD student (from Oct 2025)
Mia Catharina Nikolaisen Heimdal	Lecturer / Practice coordinator
Anne Gyri Gløersen	Lecturer (50%)

Guest researchers

Alma Mulac, Anette Vik Jøsendal, Sarah Hiorth Andersen, Mollie Wood

EMAIL: h.m.e.nordeng@farmasi.uio.no

LAYOUT: Maren Olson

WEB: <https://www.mn.uio.no/farmasi/english/research/groups/pharma-safe/>

PHOTOS: Colourbox.com

PRINT: Reprosentralen, UiO, 2025